In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Tikosyn (Pfizer)
- INDICATIONS: Conversion of atrial fibrillation and atrial flutter to normal sinus rhythm
- CLASS: Antiarrhythmic, Antiarrhythmic class III
- HALF-LIFE: 10 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Bictegravir/Emtricitabine/Tenofovir Alafenamide, Chlorpromazine, Cimetidine, Co-Trimoxazole, Degarelix, Dolutegravir, Fluphenazine, Hydrochlorothiazide, Itraconazole, Ketoconazole, Medroxyprogesterone, Megestrol, Mesoridazine, Phenothiazines, Prochlorperazine, Progestins, Promethazine, Quinine, Ranolazine, Thioridazine, Trifluoperazine, Trilaciclib, Trimethoprim, Vandetanib, Verapamil, Voriconazole, Zuclopenthixol
- See adverse reactions attributed to class:
Contra-indicated in patients with congenital or acquired long QT syndromes.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
